Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6WY0

CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-40 A.K.A 7-[(1R)-1-phenyl-3-{[(1r,4r)-4-phenylcyclohexyl]amino}propyl]-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine

Summary for 6WY0
Entry DOI10.2210/pdb6wy0/pdb
DescriptorMyeloperoxidase light chain, Myeloperoxidase heavy chain, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... (10 entities in total)
Functional Keywordsmyeloperoxidase, mpo, heme, oxidoreductase
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains8
Total formula weight272210.84
Authors
Khan, J.A. (deposition date: 2020-05-12, release date: 2020-10-14, Last modification date: 2023-11-15)
Primary citationShaw, S.A.,Vokits, B.P.,Dilger, A.K.,Viet, A.,Clark, C.G.,Abell, L.M.,Locke, G.A.,Duke, G.,Kopcho, L.M.,Dongre, A.,Gao, J.,Krishnakumar, A.,Jusuf, S.,Khan, J.,Spronk, S.A.,Basso, M.D.,Zhao, L.,Cantor, G.H.,Onorato, J.M.,Wexler, R.R.,Duclos, F.,Kick, E.K.
Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase.
Bioorg.Med.Chem., 28:115723-115723, 2020
Cited by
PubMed Abstract: Myeloperoxidase (MPO) is a heme peroxidase found in neutrophils, monocytes and macrophages that efficiently catalyzes the oxidation of endogenous chloride into hypochlorous acid for antimicrobial activity. Chronic MPO activation can lead to indiscriminate protein modification causing tissue damage, and has been associated with chronic inflammatory diseases, atherosclerosis, and acute cardiovascular events. Triazolopyrimidine 5 is a reversible MPO inhibitor; however it suffers from poor stability in acid, and is an irreversible inhibitor of the DNA repair protein methyl guanine methyl transferase (MGMT). Structure-based drug design was employed to discover benzyl triazolopyridines with improved MPO potency, as well as acid stability, no reactivity with MGMT, and selectivity against thyroid peroxidase (TPO). Structure-activity relationships, a crystal structure of the MPO-inhibitor complex, and acute in vivo pharmacodynamic data are described herein.
PubMed: 33007547
DOI: 10.1016/j.bmc.2020.115723
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.799 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon